Products for Research Use Only

CL2A-SN-38

CAT: 0804-HY-128946-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-128946-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
CL2A-SN-38 is a agent-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody agent conjugate (ADC) . CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active agents within tumor cells and in the tumor microenvironment, resulting in bystander effects[1].
CAS Number
1279680-68-0
UNSPSC
12352203
Hazard Statement
H301
Target
Drug-Linker Conjugates for ADC
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/cl2a-sn-38.html
Purity
99.89
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(O[C@](C1=C(CO2)C(N3CC4=C(CC)C5=CC(O)=CC=C5N=C4C3=C1)=O)(CC)C2=O)OCC6=CC=C(NC([C@H](CCCCN)NC(COCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN7N=NC(CNC(C8CCC(CN9C(C=CC9=O)=O)CC8)=O)=C7)=O)=O)=O)C=C6
Molecular Formula
C73H97N11O22
Molecular Weight
1480.61
Precautions
H301
References & Citations
[1]Cardillo TM, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17 (10) :3157-69.|[2]Thomas M Cardillo, et al. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011 May 15;17 (10) :3157-69.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, stored under nitrogen)
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
Camptothecins